Pharmaceutical Pricing Strategy

By Jeremy Spivey, Senior Research Analyst In an effort to expand Chinese citizens' access to certain high-volume pharmaceutical products, the Chinese government has committed to expanding a price-squeezing tendering system to the entire country. The...

By Shaylyn Pike, Senior Research Analyst The managed markets function in the United States has been around for many years. Since the arrival of Medicare, Medicaid and the health insurance industry in its current form, drug and device companies have...

By Jeremy Spivey,Senior Research Analyst The first few decisions of Germany’s new drug pricing body have arrived, and the results are mixed. Brilique (known as Brilinta in the United States) in December became the first product to complete the new product...

By Shaylyn Pike,Senior Research Analyst New research finds that 50 percent of pharmaceutical companies prefer to launch new products in the U.S. before any other market. Half of the drug manufacturers profiled in a new Cutting Edge Information study...

Cutting Edge Information's new "Pharmaceutical Pricing Strategy" report concludes that drug pricing teams are working to meet payer demand earlier and more directly. Drug pricing departments are now involved in earlier stages of drug development to maximize drug...

By Michelle Vitko,Research Analyst Recently, I wrote a piece on the need for portfolio management teams to plan well ahead of patent expiry to maximize the number of tactics available to them to extend the lifecycle of the products in their portfolio....

By Shaylyn Pike,Senior Research Analyst As the European Union attempts to prevent its dissolution as its financial crisis deepens, the life sciences industry watches with concern. If the European economy collapses, so does a significant portion of the...

By Jeremy Spivey,Senior Research Analyst After 10 years of deliberations, a draft of India’s National Pharmaceutical Pricing Policy has been released. Though the document will remain open for comments through the end of November, the final policy is...

By Michelle Vitko,Research Analyst The earlier pharmaceutical companies begin mapping out their portfolio management options, the more strategies will be available to them and the more success they will have in general. In fact, a senior director at a...

By Jeremy Spivey,Senior Research Analyst The Prescription Drug Cost Reduction Act, a bill introduced by Sen. Herb Kohl on October 13th, seeks to impose a number of new measures to reduce the US government's budget outlay on pharmaceutical and biotechnology...